Commercial Potential

We encourage executive and commercial leaders to pressure-test their confidence in commercial potential by asking
5 CRITICAL QUESTIONS.
Answering NO to any of these questions may cost tens of millions in value.

  • 1. Market Size

    DO YOU KNOW: The details behind the epidemiology figures you reference and how they might misstate potential?

    KEY ISSUE: Typical epidemiology studies are not designed to support commercial forecasting.

  • 2. Market Structure

    DO YOU UNDERSTAND: How key market segments, such as patient age/type and anticipated payer coverage of studied vs. non-studied populations might impact clinical trial design and commercial potential for your indication?

    KEY ISSUE: Critical to identify the addressable patient populations from study protocol through approved PI.

  • 3. Market Share

    CAN YOU EXPLAIN: What happened to the “other half” of market share when you were advised to model market share by simply cutting physician preference share by 50%?

    KEY ISSUE: Structured and defensible share calibration is necessary for an accurate forecast.

  • 4. Price

    ARE YOU CONTEMPLATING: How pricing dynamics may impact market share and patient access?

    KEY ISSUE: Proper design of payer market research, analogue selection & value framework supports effective pricing.

  • 5. Global Projections

    ARE YOU CONFIDENT: That projecting ex-US potential by simply applying the “25% rule of thumb” accurately represents your asset’s potential?

    KEY ISSUE: Credibly assert ex-US projections even at early development stage.

The proverbial 30,000-foot view is not sufficient
to answer those 5 critical questions or support
diligence and planning objectives

Achieve the confidence of the Sentero 1K’VIEW™

1K’VIEW™ Commercial Assessment Components

FIT-FOR-PURPOSE ASSESSMENT BASED ON CLIENT’S
STAGE OF DEVELOPMENT AND COMPANY OBJECTIVES

Sentero’s Commercial Assessment Portfolio

OUR CLIENTS INCLUDE PRE-REVENUE AND ON-MARKET
SPECIALTY AND LARGE PHARMACEUTICAL COMPANIES

WE HAVE CONDUCTED >80 COMMERCIAL ASSESSMENTS
COVERING US AND GLOBAL COMMERCIAL OPPORTUNITIES

85% OF OUR ASSESSMENTS HAVE BEEN FOR RARE
DISEASE/GENE THERAPY AND ONCOLOGY INDICATIONS


Rare Disease &
Gene Therapies

  • Neurodegenerative

  • Neurodevelopmental

  • Myoclonic & Progressive Epilepsies

  • Inborn Errors of Metabolism

  • Lipid Storage Disorders

  • Lysosomal Storage Disorders

  • Nervous System Disorders

  • ARG-1 Deficiency

  • Ataxia Telangiectasia

  • Frontotemporal Dementia

  • Spinocerebellar Ataxia Type 1

  • Ocular Conditions

  • Dermatological Conditions 


Oncology

  • rGBM/Brain

  • Breast

  • Melanoma

  • Colorectal

  • Bladder

  • Head & Neck


Cardiopulmonary/Other

  • Pulmonary Arterial Hypertension

  • Idiopathic Pulmonary Fibrosis

  • Progressive Pulmonary Fibrosis

  • Asthma/COPD

  • Genetic Cardiomyopathies

  • Degenerative Disc Disease

  • Type 1 Diabetes

  • Device